Cargando…

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer

AIM: We aimed to evaluate the efficacy and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression in unresectable pancreatic cancer. METHODS: The expression of BRCA1 mRNA in tumor tissues of 25 patients with pancreatic cancer was detected in this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Juan, Zhu, Linxi, Sha, Huizi, Zou, Zhengyun, Shen, Jie, Kong, Weiwei, Zhao, Lianjun, Gu, Qing, Yu, Lixia, Qiu, Yudong, Liu, Baorui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663848/ https://www.ncbi.nlm.nih.gov/pubmed/36387089 http://dx.doi.org/10.3389/fonc.2022.1015232

Ejemplares similares

AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study
por: Dai, Wangshu, et al.
Publicado: (2021)

Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer
por: Shen, Jie, et al.
Publicado: (2014)

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019)

Identification of a novel gene signature for the prediction of recurrence in HCC patients by machine learning of genome-wide databases
por: Shen, Jie, et al.
Publicado: (2020)

Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer
por: Kwan, Byung Soo, et al.
Publicado: (2023)

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel
por: Wang, Lifeng, et al.
Publicado: (2008)

Disappearance of bone metastases in chemotherapy-resistant gastric cancer treated with antigen peptide-pulsed dendritic cell-activated cytotoxic T lymphocyte immunotherapy: A case report
por: Du, Juan, et al.
Publicado: (2018)

Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
por: Kiriukova, Mariia, et al.
Publicado: (2020)

Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer
por: Shindo, Yoshitaro, et al.
Publicado: (2014)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan
por: Furuse, Junji
Publicado: (2019)

Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer
por: Moningi, Shalini, et al.
Publicado: (2022)

Impact of Splenectomy on Thrombocytopenia, Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer
por: Donahue, Timothy R., et al.
Publicado: (2010)

Gastric metastasis from sphenoid sinus melanoma: A case report
por: ZHAO, LIANJUN, et al.
Publicado: (2015)

Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy
por: Du, Juan, et al.
Publicado: (2022)

Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysis
por: Tezuka, Shun, et al.
Publicado: (2021)

BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy
por: Gao, Yong, et al.
Publicado: (2013)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
por: Su, Shu, et al.
Publicado: (2016)

Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
por: Su, Shu, et al.
Publicado: (2017)

Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma
por: Gurka, Marie K., et al.
Publicado: (2017)

Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy
por: Ishii, Noriko, et al.
Publicado: (2020)

Brachytherapy Drainage Catheter and Chemotherapy for Unresectable Pancreatic Carcinoma Combined with Obstructive Jaundice
por: Jiao, Dechao, et al.
Publicado: (2022)

The plasma levels of 12 cytokines and growth factors in patients with gastric cancer
por: Zou, Zhengyun, et al.
Publicado: (2018)

Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer
por: Lu, Changchang, et al.
Publicado: (2022)

The Efficacy and Safety of Hypofractionated Radiation Therapy With Tomotherapy for Advanced or Recurrent Hepatocellular Carcinoma
por: Shen, Jie, et al.
Publicado: (2021)

Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA‐negative breast cancers
por: Xu, Ye, et al.
Publicado: (2017)

Plasma mRNA as liquid biopsy predicts chemo-sensitivity in advanced gastric cancer patients
por: Shen, Jie, et al.
Publicado: (2017)

Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study
por: Liu, Shupeng, et al.
Publicado: (2019)

Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma
por: Kim, Hyemin, et al.
Publicado: (2021)

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy
por: Su, Shu, et al.
Publicado: (2015)

Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment
por: Zhang, Zhen, et al.
Publicado: (2018)

Recent Progress on Therapeutic Vaccines for Breast Cancer
por: Zhang, Lianru, et al.
Publicado: (2022)

An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer
por: Lin, Mao, et al.
Publicado: (2017)

Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer
por: Nishiofuku, Hideyuki, et al.
Publicado: (2015)

Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer
por: Ma, Sung Jun, et al.
Publicado: (2018)

Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients
por: Kuroda, Taira, et al.
Publicado: (2017)

The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy
por: Park, Hyunkyung, et al.
Publicado: (2019)

Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines
por: Zou, Zhengyun, et al.
Publicado: (2012)

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer
por: Lu, Changchang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9lepquh702695issgo9tsdrj5m